Medinice S.A. — M&A Activity 2026

Apr 21, 2026

Report Content TheManagement Board of Medinice S.A. with its registered office in Warsaw("Issuer") informs that on 21 April 2026 due diligence concerning theCoolCryo medical device commenced. The purpose of the due diligence isfor the potential acquirer to obtain knowledge about the legal andfactual status of CoolCryo, and then to prepare an purchase offer ofCoolCryo. The potential acquirer for whose benefit the due diligence isbeing conducted is a large industry entity operating on an internationalscale.TheIssuer's Management Board reminds that this is the second andindependent process of this type in relation to CoolCryo. The first onebegun directly after the signing of the letter of intent, about whichthe Company informed on 23 January this year in ESPI report No. 4/2026.CoolCryois a medical device intended for the treatment of cardiac arrhythmiasthrough the performance of surgical cryoablation. CoolCryo has beenapproved for marketing in the United States market, of which the Issuerinformed in current ESPI report No. 5/2026 dated 13 February 2026.

TheIssuer publishes this information due to the fact that the potentialdisposal of CoolCryo, which may result from the due diligence, may havea very significant positive impact on the financial situation andresults of the Issuer.